Mitsubishi Tanabe Pharma Corp - Strategy, SWOT and Corporate Finance Report

Mitsubishi Tanabe Pharma Corp - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company

Key Highlights

Mitsubishi Tanabe Pharma Corp (Mitsubishi Tanabe), a subsidiary of Mitsubishi Chemical Holdings Corp, identifies, develops, manufactures, procures and commercializes ethical drugs and over-the-counter (OTC) pharmaceutical products. The company develops ethical drugs for autoimmune disease, diabetes, kidney diseases, central nervous system (CNS) disorders and others. It also develops vaccines for preventing various infectious diseases. The company markets its products to wholesalers, hospitals, clinics, and drugstores. It has subsidiaries in Asia, Europe and North America. Mitsubishi Tanabe is headquartered in Chuo-ku, Osaka, Japan.

Scope

  • Detailed information on Mitsubishi Tanabe Pharma Corp required for business and competitor intelligence needs
  • A study of the major internal and external factors affecting Mitsubishi Tanabe Pharma Corp in the form of a SWOT analysis
  • An in-depth view of the business model of Mitsubishi Tanabe Pharma Corp including a breakdown and examination of key business segments
  • News about Mitsubishi Tanabe Pharma Corp, such as business expansion, restructuring, and contract wins
  • Large number of easy-to-grasp charts and graphs that present important data and key trends

Reasons to buy

  • Gain understanding of Mitsubishi Tanabe Pharma Corp and the factors that influence its strategies.
  • Track strategic initiatives of the company and latest corporate news and actions.
  • Assess Mitsubishi Tanabe Pharma Corp as a prospective partner, vendor or supplier.
  • Support sales activities by understanding your customers' businesses better.
  • Stay up to date on Mitsubishi Tanabe Pharma Corps business structure, strategy and prospects.

Note: Some sections may be missing if data is unavailable for the company.

Companies mentioned

Kissei Pharmaceutical Co Ltd

Astellas Pharma Inc

Tsumura & co

Taisho Pharmaceutical Holdings Co Ltd

Chugai Pharmaceutical Co Ltd

Daiichi Sankyo Co Ltd

Kissei Pharmaceutical Co Ltd

Astellas Pharma Inc

Tsumura & co

Taisho Pharmaceutical Holdings Co Ltd

Chugai Pharmaceutical Co Ltd

Daiichi Sankyo Co Ltd

Table of Contents

Table of Contents

Table of Contents

List of Tables

List of Figures

Section 1 - About the Company

Mitsubishi Tanabe Pharma Corp - Key Facts ...

Table of Contents

Table of Contents

List of Tables

List of Figures

Section 1 - About the Company

Mitsubishi Tanabe Pharma Corp - Key Facts

Mitsubishi Tanabe Pharma Corp - Key Employees

Mitsubishi Tanabe Pharma Corp - Key Employee Biographies

Mitsubishi Tanabe Pharma Corp - Major Products and Services

Mitsubishi Tanabe Pharma Corp - History

Mitsubishi Tanabe Pharma Corp - Company Statement

Mitsubishi Tanabe Pharma Corp - Locations And Subsidiaries

Head Office

Other Locations & Subsidiaries

Joint Venture

Section 2 – Company Analysis

Company Overview

Mitsubishi Tanabe Pharma Corp - Business Description

Product Category: Domestic Ethical Drugs

Performance

Product Category: OTC Products

Performance

Product Category: Others

Performance

Product Category: Overseas Ethical Drugs

Performance

Product Category: Royalty Revenue

Performance

Geographical Segment: Asia

Performance

Geographical Segment: Europe

Performance

Geographical Segment: Japan

Performance

Geographical Segment: North America

Performance

Geographical Segment: Others

Performance

R&D Overview

Mitsubishi Tanabe Pharma Corp - SWOT Analysis

SWOT Analysis - Overview

Mitsubishi Tanabe Pharma Corp - Strengths

Mitsubishi Tanabe Pharma Corp - Weaknesses

Mitsubishi Tanabe Pharma Corp - Opportunities

Mitsubishi Tanabe Pharma Corp - Threats

Mitsubishi Tanabe Pharma Corp - Key Competitors

Section 3 – Company Financial Ratios

Financial Ratios - Capital Market Ratios

Financial Ratios - Annual Ratios

Performance Chart

Financial Performance

Financial Ratios - Interim Ratios

Financial Ratios - Ratio Charts

Section 4 – Company’s Lifesciences Financial Deals and Alliances

Mitsubishi Tanabe Pharma Corp, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019

Mitsubishi Tanabe Pharma Corp, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019

Mitsubishi Tanabe Pharma Corp, Recent Deals Summary

Section 5 – Company’s Recent Developments

Apr 26, 2019: BioInvent receives €0.75 million milestone under Mitsubishi Tanabe Pharma partnership

Mar 20, 2019: Mitsubishi Tanabe Pharma: Aiming to expand our sales and to strengthen our business foundations in the growing ASEAN market Establishment of sales subsidiary in Malaysia and Vietnam representative officeAiming to expand our sales and to strengthen our business foundations in the growing ASEAN market Establishment of sales subsidiary in Malaysia and Vietnam representative office

Oct 09, 2018: Astellas, Mitsubishi Tanabe Pharma, and Daiichi Sankyo announce second public recruitment offering of "Joinus", a joint research program to discover new drugs using drug-repositioning compound library

Sep 28, 2018: New country manager brings significant business leadership and healthcare expertise to Mitsubishi Tanabe Pharma Canada

Sep 26, 2018: Mitsubishi Tanabe Pharma announce company name changes of our oversea subsidiaries

Sep 18, 2018: Mitsubishi Tanabe Pharma included in the Dow Jones Sustainability Asia Pacific Index

Jul 02, 2018: Mitsubishi Tanabe Pharma and Osaka University co-found the Department of Neuro-Medical Science - Toward the Innovative Drug Discovery for refractory Neurological Diseases

Jul 02, 2018: Mitsubishi Tanabe Pharma and Osaka University co-found the “Department of Neuro-Medical Science”

Jul 02, 2018: Mitsubishi Tanabe Pharma: Open Call for Applicants for investigator-Initiated Clinical Research Funds

May 30, 2018: Daiichi Sankyo Announces Launch of Immune-mediated Inflammatory Diseases Consortium for Drug Development

Section 6 – Appendix

Methodology

Ratio Definitions

About GlobalData

Contact Us

Disclaimer

List of Tables

List of Tables

Mitsubishi Tanabe Pharma Corp, Key Facts

Mitsubishi Tanabe Pharma Corp, Key Employees

Mitsubishi Tanabe Pharma Corp, Key Employee Biographies

Mitsubishi Tanabe Pharma ...

List of Tables

Mitsubishi Tanabe Pharma Corp, Key Facts

Mitsubishi Tanabe Pharma Corp, Key Employees

Mitsubishi Tanabe Pharma Corp, Key Employee Biographies

Mitsubishi Tanabe Pharma Corp, Major Products and Services

Mitsubishi Tanabe Pharma Corp, History

Mitsubishi Tanabe Pharma Corp, Other Locations

Mitsubishi Tanabe Pharma Corp, Subsidiaries

Mitsubishi Tanabe Pharma Corp, Joint Venture

Mitsubishi Tanabe Pharma Corp, Key Competitors

Mitsubishi Tanabe Pharma Corp, Ratios based on current share price

Mitsubishi Tanabe Pharma Corp, Annual Ratios

Mitsubishi Tanabe Pharma Corp, Annual Ratios (Cont...1)

Mitsubishi Tanabe Pharma Corp, Annual Ratios (Cont...2)

Mitsubishi Tanabe Pharma Corp, Interim Ratios

Mitsubishi Tanabe Pharma Corp, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019

Mitsubishi Tanabe Pharma Corp, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019

Mitsubishi Tanabe Pharma Corp, Recent Deals Summary

Currency Codes

Capital Market Ratios

Equity Ratios

Profitability Ratios

Cost Ratios

Liquidity Ratios

Leverage Ratios

Efficiency Ratios

List of Figures

List of Figures

Mitsubishi Tanabe Pharma Corp, Performance Chart (2015 - 2019)

Mitsubishi Tanabe Pharma Corp, Ratio Charts

Mitsubishi Tanabe Pharma Corp, Pharmaceuticals & Healthcare, ...

List of Figures

Mitsubishi Tanabe Pharma Corp, Performance Chart (2015 - 2019)

Mitsubishi Tanabe Pharma Corp, Ratio Charts

Mitsubishi Tanabe Pharma Corp, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019

Mitsubishi Tanabe Pharma Corp, Pharmaceuticals & Healthcare, Deals by Type, 2013 to YTD 2019

    Pricing

Discounts available for multiple report purchases.

reportstore@marketline.com
+44 (0) 161 359 5817

Saved reports